Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology
Blank Bio, an applied AI research lab training foundation models for RNA, today announced the closing of a $7.2 million seed financing and a strategic collaboration with Pacific Biosciences (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions. Blank Bio is building RNA foundation models that learn directly from the molecular complexity of tumor transcriptomes to improve patient-level prediction across oncology. Proceeds from the financing will support continued model development, expanded collaborations with pharmaceutical and diagnostic companies, and new long-read RNA-seq datasets to support applications in biomarkers, clinical trial design, and diagnostics.
